Views & Analysis | Perspectives on pharma industry issues

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Articles

The Pharma Marketing Show Europe 2012: event overview

Rebecca Aris provides an overview of day one at the ‘Pharma Marketing Show Europe 2012’ event as pharmaphorum’s marketing excellence month commences. The recent ‘Pharma Marketing Show Europe 2012’ event, held by health network communication in London was aimed at...

Articles

A new look at patient communications in outcomes-driven heal...

Susan Carr addresses the importance of effectively communicating patient self-management techniques in tackling patient adherence and the role that digital can play in this communication. Around the world, healthcare markets are changing rapidly as patients, healthcare providers and payers demand lower costs, higher quality...

Articles

Challenges to personalised medicine

As our personalised medicine theme comes to an end, Duncan McHale, Vice President of Global Exploratory Development at UCB, shares his thoughts on personalised medicine. Duncan McHale has a long history in personalised medicines. He helped to set up the pharmacogenomics programme at Pfizer...

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access